hnRNP-A1 binds to the IRES of MELOE-1 antigen to promote its translation in stressed melanoma cells.
Maud CharpentierEmilie DupréAgnès FortunFloriane BriandMike MaillassonEmmanuelle ComCharles PineauNathalie LabarrièreCatherine RabuFrançois LangPublished in: Molecular oncology (2021)
The major challenge in antigen-specific immunotherapy of cancer is to select the most relevant tumor antigens to target. To this aim, understanding their mode of expression by tumor cells is critical. We previously identified a melanoma-specific antigen, melanoma-overexpressed antigen 1 (MELOE-1)-coded for by a long noncoding RNA-whose internal ribosomal entry sequence (IRES)-dependent translation is restricted to tumor cells. This restricted expression is associated with the presence of a broad-specific T-cell repertoire that is involved in tumor immunosurveillance in melanoma patients. In the present work, we explored the translation control of MELOE-1 and provide evidence that heterogeneous nuclear ribonucleoprotein A1 (hnRNP-A1) binds to the MELOE-1 IRES and acts as an IRES trans-activating factor (ITAF) to promote the translation of MELOE-1 in melanoma cells. In addition, we showed that endoplasmic reticulum (ER) stress induced by thapsigargin, which promotes hnRNP-A1 cytoplasmic translocation, enhances MELOE-1 translation and recognition of melanoma cells by a MELOE-1-specific T-cell clone. These findings suggest that pharmacological stimulation of stress pathways may enhance the efficacy of immunotherapies targeting stress-induced tumor antigens such as MELOE-1.
Keyphrases
- stress induced
- long noncoding rna
- poor prognosis
- endoplasmic reticulum
- end stage renal disease
- ejection fraction
- signaling pathway
- chronic kidney disease
- skin cancer
- newly diagnosed
- dendritic cells
- prognostic factors
- squamous cell carcinoma
- binding protein
- long non coding rna
- immune response
- amino acid
- lymph node metastasis